Theriva Biologics, Inc. has reported its operational highlights and financial results for 2025, showcasing significant advancements in its therapeutic pipeline and strategic financial maneuvers. The clinical-stage biotech firm ended the year with $13.1 million in cash, which has since increased to approximately $15.2 million, ensuring funding through early 2027. Despite a net loss of $25.3 million, the company noted a decrease in overall operating costs, particularly in research and development as major trials concluded.

This financial stability allows Theriva to focus on its oncology pipeline, particularly its lead oncolytic virus candidate, VCN‑01, which is advancing toward pivotal trials for pancreatic ductal adenocarcinoma and retinoblastoma. The recent licensing of its recombinant enzyme asset, SYN‑020, to Rasayana Therapeutics further alleviates financial pressure while potentially yielding significant future revenue through milestone payments and royalties.

For professionals in longevity and healthspan research, Theriva’s strategic moves reflect a growing emphasis on oncology therapeutics, which could have implications for the development of age-related cancer treatments. I encourage you to explore the full article for a deeper understanding of Theriva’s promising trajectory.

Source: longevity.technology